Medical device company SI-BONE has secured the US Food and Drug Administration (FDA) 510(k) clearance on a revised indication statement to extend the application of its iFuse Implant System (iFuse).

Studies have demonstrated the device’s ability to reduce pain, resulting in improved patient function and quality of life.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The revised indication statement is based on the safety and effectiveness data from retrospective studies, as well as three prospective clinical trials conducted on the iFuse.

"This is a significant milestone in the evolution of the treatment of SI joint dysfunction and clearly sets iFuse apart from any other surgical treatment option."

SI-BONE president and CEO Jeffrey Dunn said: "This is a significant milestone in the evolution of the treatment of SI joint dysfunction and clearly sets iFuse apart from any other surgical treatment option.

"No other surgical treatment option for SI joint dysfunction is supported by prospective data and now with over 21,000 procedures performed worldwide, iFuse is clearly the surgical treatment of choice for SI joint dysfunction due to SI joint disruption or degenerative sacroiliitis."

The iFuse Implant is a minimally invasive surgical device, which features a patented triangular shape that provides 31 times the rotational resistance of a screw.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device features titanium implants coated with a porous titanium plasma spray (TPS), providing an interference surface to decrease implant motion and allow biological fixation to support long-term fusion.

It is intended to be used for sacroiliac fusion for conditions such as sacroiliac joint dysfunction, which is a result of sacroiliac joint disruption and degenerative sacroiliitis.

It comprises conditions whose symptoms begin during pregnancy or the peripartum period, and have lasted postpartum for more than six months.